Call for Abstracts
Call for Abstracts has closed.
Notification of Acceptance/Rejection has been sent out to the applicants.
Please contact the secretariat (email@example.com) if you have not received.
- Abstract submission period
- Call for abstracts
- Late-breaking abstracts
- Plenary Session
- Travel Award
- Publication in “Annals of Oncology”
- Disclosure of Conflict of Interest at the Japanese Society of Medical Oncology 2017 Annual Meeting
- Abstract Submission
- Confirmation / Modification / Deletion of submitted abstract / Additional submission
- Acceptance/rejection notification
- Abstract Submission / Confirmation / Modification / Deletion of submitted abstract / Additional submission Page
- Inquiry (Technical problems / questions)
Abstract Submission Period
Abstract submission opening: Thursday, December 15, 2016
Abstract submission closing: Thursday, February 2, 2017 at noon JST
Thursday, February 9, 2017 at noon JST
Tuesday, February 14, 2017 at noon JST
Call for Abstracts
International Session / Symposium / Workshop
International Session(Open Call / Partially Invited)
Comprehensive Symptom Screening and Early Palliative care
—From the Start of Cancer Treatment—
It has been suggested that early palliative care may affect not only quality of life but also cancer treatment, and the importance of engaging in palliative care from soon after cancer diagnosis is now being recognized. With respect to palliative care at designated cancer care hospitals, screening for symptoms from the time of diagnosis and appropriate intervention are among the stated conditions for designation as a cancer care hospital. However, early screening depends on the situations in these cancer care hospitals as well as local circumstances, and there is huge variation in how this is actually dealt with, including various problems with systems and staffing. In this session, we will hear about early palliative care in Canada, which is a pioneer in this area, followed by a description of initiatives in three hospitals that are actively engaged in palliative care screening using a range of different methods, with the aim of obtaining hints on symptomatic screening for palliative care in future.
Symposium(Open Call / Partially Invited)
Newest knowledge in gastric cancer
Although the molecular targeted agents of trastuzumab and ramucirumab have already come into use as standard chemotherapy for gastric cancer, many other novel agents have proved unsuccessful during development. Immune checkpoint inhibitors are now the focus of attention, as they have been found to be effective against gastric cancer. In this session we will discuss the status of new drug development and future directions on the basis of clinical and biological characteristics.
Workshop(Open Call / Partially Invited)
Current landscape and future perspectives of biomarker study in breast cancer
It has been clarified that breast cancer is not one disease, but heterogeneous tumor by recent gene expression profiling and genome sequencing. To provide optimal treatment by these genomic information, so called "precision medicine" is needed. In addition, it is very important to consider immune effect in host side for breast cancer therapy. In this session, we discuss currently available biomarkers or promising future biomarkers.
Free paper (Oral / Poster Presentation)
JSMO2017 is accepting abstracts for free paper.
Presentation style will be either Oral presentation or Poster presentation.
Please select the abstract category from the list below. (The 1st & 2nd choices are required.)
Abstract Category for Free Paper
|4||Head and neck cancer|
|9||Hepatoma / HCC|
|10||Biliary tract cancer / Pancreatic cancer|
|12||Uterin cancer / Ovarian cancer|
|13||Other gynecological cancer|
|15||Endocrine tumors / Thyroid cancer|
|17||Bone and soft tissue tumors|
|20||Other hematological malignancies|
|21||Cancer of unknown primary|
|29||Innovative drug research & development|
|30||Early clinical development|
|34||Clinical trial support|
|38||Other anti-cancer drugs|
|41||Trials in progress (a)|
|42||Molecular and genetic diagnosis|
|48||Regional medical network|
|49||Team medical care|
|56||Patient advocacy / Cancer survivorship|
|57||Adolescent and Young Adult Oncology|
(a) Please note that if you select, “Trials in Progress,” your abstract will NOT be included in the JSMO2017 USB abstract or any other available electronic program, such as “My schedule.” Your submitted abstracts will be printed and handed out to the participants at the room where you deliver your presentation.
* Abstract Encouragement Award
- Age limitation: The first author must be under the age 40 (as of July 29, 2017)
- Once you are nominated as a candidate, you will be requested to submit an electronic data for review in May, 2017.
- If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Encouragement Award.
* All submitted abstracts will be reviewed by the Peer Review Committee, and will be decided based on the study contents, ethical aspects, and etc. Please register the style of presentation (oral or poster). However, it will be the Chairman’s decision on the presentation style, presentation, session, as well as acceptance/rejection.
JSMO2017 will be holding deep discussions based on leading-edge research result, and calls for “Late-breaking” abstracts.
If you are applying for Late-breaking abstracts, please select “Yes” for the question, “Are you applying for late-breaking abstracts?” and submit an outline and predicted result of your research as interim registration in the abstract text box.
Please complete the submission by Friday, April 14, 2017.(You will be notified by the Secretariat to complete the abstract submission at the beginning of April, 2017.)
* Your abstract may not be included in the JSMO2017 USB Abstract, if the complete abstract is submitted later than Friday, April 14. This is due to the USB Abstract must be prepared at a certain time before the congress.
Plenary Session (International Session)
JSMO2017 is planning to have “Plenary Sessions”.
* The topic of the plenary session will be selected from among the submitted titles.
Abstracts submitted by young researchers who live outside of Japan will be reviewed by the JSMO2017 Organizer. The presenters will receive partial travel grant for their outstanding work.
|*||JPY50,000-100,000 of travel support to investigators from Asia. (depending on the quality of abstract)|
|*||JPY150,000 of travel support to investigators from US or EU.|
|*||If you are receiving support from any company, your application for Travel Award will be not qualified to receive this award.|
Publication in “Annals of Oncology”
Abstracts (oral/ poster) submitted in English for JSMO2017 Annual Meeting will be published in ESMO/JSMO Scientific Journal, supplement to “Annals of Oncology” (Oxford University Press).
If you wish to have your abstract published in “Annals of Oncology,” please select “Yes”.
* Terms to be published in Journal "Annals of Oncology" as to poster presentation:
|(1)||Your abstract must be accepted for poster presentation.|
|(2)||To be published in the Journal “Annals of Oncology,” the posting fee (5,000JPY) must be paid in addition to the Congress registration fee.|
|(3)||The payment must be made through the online pre-registration site (From the beginning of April, 2017 to June, 2017)|
* How to Register:
|(1)||When you enter the pre-registration site, your poster presentation ID number and title will show up. If you wish to be published in the journal, “Annals of Oncology,” please check the applicable box(es).|
|(2)||Please proceed with making your payment by credit card for both for the publishing and registration for the congress.|
Disclosure of Conflict of Interest at the Japanese Society of Medical Oncology 2017 Annual Meeting
The first authors and directors (who are in charge of the studies, usually last author) must disclose applicable COI (Conflict of Interest) of your presentation at the meeting. Please inform the COI from January 1, 2016 to December 31, 2016.
For oral presentation, please use the following slide as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.
We accept abstracts submitted online only through the submission system.
You can go to the submission page from the button “Abstract Submission” located at the bottom of this page.
|(1)||Author information and abstracts must be submitted in English.|
|(2)||Abstract title must be up to 120 single-byte characters.|
|(3)||Abstract text must be up to 2,000 single-byte characters.|
|(4)||The maximum of 10 authors (first author & co-authors) can be registered.|
|(5)||The maximum of 10 affiliations (including the affiliation of the first author) can be registered.|
|(6)||If possible, please structure your abstract with:
|(7)||Any chart or diagram cannot be included.|
|(8)||Regarding the special characters, please refer here.|
|(9)||In the registration page, you will be asked to enter the information such as “application for Late-breaking abstracts”, “application for Travel Award”, “Publication in Annals of Oncology” as well as, COI information.
Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission
You can access to confirm/modify/delete/add abstracts during the abstract submission period. The ID number and password will be required to enter the page (confirm/modify/delete/add abstracts).
Notification of acceptance/rejection will be sent by email, by May, 2017, to the first author.
- Abstract Submission
Confirmation / Modification / Deletion of submitted abstract & Additional submission Page
- Confirmation / Modification / Deletion / Additional submission
Inquiries for Abstract Submission
c/o Congress Corporation
3-6-13 Awajimachi, Chuo-ku, Osaka 541-0047, Japan
Phone: +81-6-6229-2555 Fax: +81-6-6229-2556